T2 Biosystems (NASDAQ:TTOO) said on Thursday it had planned to complete development of, and commercialize, a diagnostic test to detect early Lyme disease.
The company expects to begin marketing and sales in the United States as a Laboratory Developed Test (LDT) in 2023.
Read more at: https://seekingalpha.com/news/3891117-t2-biosystems-to-develop-commercialize-diagnostic-test-for-early-lyme-disease
